Type to search




Benchmark completes sale of subsidiary. Benchmark has announced that it has completed the sale of its wholly owned subsidiary FVG Ltd. (“FishVet”) to Pharmaq, part of the global animal health company Zoetis. The sale comprises Benchmark’s veterinary and diagnostic services activities in the UK, Ireland, Norway and Chile.

The transaction is another significant step in Benchmark’s strategy to exit non-core areas and focus on its core areas of genetics, health and advanced nutrition in the global aquaculture markets.

Trond Williksen, CEO, commented:

“This divestment represents a significant step forward in our strategy to become a streamlined, profitable business focused on our key areas of competency.”

“The FishVet team is a highly talented group. I would like to thank every member of the team and wish them success in the future.”

Founded in 2000, Benchmark has been built through organic innovation and strategic acquisitions. In 2013, they listed on the AIM market of the London Stock Exchange.

Benchmark develop products and solutions in genetics, health and nutrition that improve performance, animal health and welfare, and reduce environmental impact across the production cycle. Their aim is to be aquaculture’s leading supplier of solutions in genetics, health and specialist nutrition. Benchmark was founded upon the need to build a sustainable food chain.